15 Participants Needed

Neurofeedback for Suicide Prevention

PR
Overseen ByPhilip R Szeszko, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: VA Office of Research and Development
Must be taking: Psychotropic medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial uses real-time brain imaging to help Veterans at high risk of suicide learn to manage their suicidal thoughts. By showing them their brain activity, they can practice ways to change it and reduce harmful thinking patterns. The goal is to improve their quality of life and reduce the risk of suicide.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it requires participants to be clinically stabilized on psychotropic medications. This suggests you may need to continue your current mental health medications.

What data supports the effectiveness of the treatment Real Time fMRI Neurofeedback for suicide prevention?

Real-time fMRI neurofeedback has shown promise in helping people with depression by allowing them to train and regulate specific brain areas related to emotions. Studies suggest it can change brain activity patterns and may help improve depressive symptoms, which could indirectly support its potential for suicide prevention.12345

Is real-time fMRI neurofeedback safe for humans?

Current studies on real-time fMRI neurofeedback, mainly for depression, suggest it is generally safe, but more research is needed to fully understand its safety, including potential side effects and long-term impacts.23456

How is the treatment Real Time fMRI Neurofeedback different from other treatments for suicide prevention?

Real Time fMRI Neurofeedback is unique because it uses real-time brain imaging to help patients learn to control their brain activity, which is different from traditional therapies that do not provide immediate feedback on brain function. This approach allows for precise targeting of brain areas involved in emotional regulation, potentially offering a novel way to address underlying issues related to suicidal thoughts.34789

Research Team

PR

Philip R Szeszko, PhD

Principal Investigator

James J. Peters Veterans Affairs Medical Center

Eligibility Criteria

This trial is for Veterans experiencing mood disorders, suicidal thoughts or behaviors, and depression. It aims to help them learn strategies to manage their brain activity related to suicide-specific rumination through feedback signals.

Inclusion Criteria

Negative pregnancy test on MRI scan days
I am a U.S. military veteran aged between 18-65.
Score greater than or equal to 10 on the Suicide Rumination Scale
See 5 more

Exclusion Criteria

I don't have any major health or brain disorders that could affect my treatment.
Current substance use disorder
History of moderate or severe traumatic brain injury
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive real-time fMRI neurofeedback to reduce suicide-specific rumination

2 weeks
2 sessions (in-person)

Transfer

Participants utilize mental strategies without receiving neurofeedback signals

1 month

Follow-up

Participants are monitored for changes in rumination, disability, functional impairment, and quality of life

1 month
Post-treatment assessments

Treatment Details

Interventions

  • Real Time fMRI Neurofeedback
Trial Overview The intervention being tested is Real Time fMRI Neurofeedback, which provides participants with live feedback on brain activation associated with repetitive focus on suicidal thoughts, in hopes of teaching them how to alter this activity.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Real-time fMRI NeurofeedbackExperimental Treatment1 Intervention
This is a pilot study to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging feedback for veterans experiencing suicide-specific rumination. All study participants will receive the intervention.

Real Time fMRI Neurofeedback is already approved in United States, European Union for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Real-time fMRI Neurofeedback for:
  • Research use for conditions such as depression, anxiety, and suicidal thoughts
๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as rt-fMRI NF for:
  • Research use for conditions such as depression, anxiety, and neurological disorders

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Findings from Research

Real-time fMRI can help patients learn to self-regulate brain circuits related to emotion and depression, showing promise as a new approach to treating affective disorders.
Initial results from fMRI-based neurofeedback (fMRI-NF) in depression are encouraging, but further clinical trials are needed to establish its efficacy and to develop practical applications for everyday use.
Neurofeedback and networks of depression.Linden, DE.[2021]
A systematic review of 11 reports from four randomized control trials found that real-time functional magnetic resonance imaging neurofeedback (rt-fMRI-nf) training showed a tendency to improve clinical depression scores, but the overall effect was not statistically significant (SMD -0.32).
While changes in brain activation patterns were observed after rt-fMRI-nf training, the evidence regarding its effectiveness for treating clinical depression remains of low certainty, indicating that more high-quality studies are needed to assess its impact on quality of life and other outcomes.
Real-Time fMRI Neurofeedback Training as a Neurorehabilitation Approach on Depressive Disorders: A Systematic Review of Randomized Control Trials.Gonzรกlez Mรฉndez, PP., Rodino Climent, J., Stanley, JA., et al.[2022]
In a pilot study involving 16 patients with major depressive disorder (MDD) and 19 healthy controls, real-time functional MRI neurofeedback (rtfMRI NF) training showed changes in brain connectivity, particularly between the insula and dorsolateral prefrontal cortex, indicating potential neurobiological impacts of the intervention.
Despite these neurobiological changes, the rtfMRI NF training did not lead to significant improvements in depressive symptoms as measured by psychometric scores, suggesting that while the technique may influence brain activity, it may not yet translate to clinical efficacy in symptom reduction.
Individual- and Connectivity-Based Real-Time fMRI Neurofeedback to Modulate Emotion-Related Brain Responses in Patients with Depression: A Pilot Study.Maywald, M., Paolini, M., Rauchmann, BS., et al.[2022]

References

Neurofeedback and networks of depression. [2021]
Real-Time fMRI Neurofeedback Training as a Neurorehabilitation Approach on Depressive Disorders: A Systematic Review of Randomized Control Trials. [2022]
Individual- and Connectivity-Based Real-Time fMRI Neurofeedback to Modulate Emotion-Related Brain Responses in Patients with Depression: A Pilot Study. [2022]
The efficacy of real-time functional magnetic resonance imaging neurofeedback for psychiatric illness: A meta-analysis of brain and behavioral outcomes. [2022]
Clinical Application of Real-Time fMRI-Based Neurofeedback for Depression. [2021]
Connectivity based Real-Time fMRI Neurofeedback Training in Youth with a History of Major Depressive Disorder. [2023]
Real-time fMRI and its application to neurofeedback. [2021]
Neurofeedback training for alcohol dependence versus treatment as usual: study protocol for a randomized controlled trial. [2022]
Functional magnetic resonance imaging (FMRI) neurofeedback: implementations and applications. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity